Article thumbnail

Detrusor Arreflexia as an End Stage of Neurogenic Bladder in HAM/TSP?

By Matheus Tannus, Davi Tanajura, Michael A. Sundberg, Paulo Oliveira, Neviton Castro and André Muniz Santos


The HTLV-1 virus is a known agent involved in the development of HAM/TSP. Past studies have typically observed patients with autonomic dysfunction consisting of detrusor overactivity and detrusor-sphincter dyssynergia, with the occasional observation of underactive detrusor or detrusor arreflexia. However, studies have not yet evaluated the progression of neurogenic bladder over time. In this paper, we describe a HAM/TSP patient with the initial development of overactive detrusor, and subsequent development of detrusor arreflexia. Given a paucity of studies characterizing the effects of HTLV-1 on the autonomic nervous system, particularly aspects controlling continence, this patient's clinical course may represent one type of end point for patients with HAM/TSP and neurogenic bladder. Further cohort or case-series studies, with particular emphasis on the progression of neurogenic bladder, are needed to evaluate the significance of this described case in relation to typical disease progression patterns

Topics: Case Report
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2009). B i s w a s ,J .W .E n g s t r o m ,Z .K a i d a r o v ae ta l . ,“ N e u r o l o g i c abnormalities in HTLV-I- and HTLV-II-infected individuals withoutovertmyelopathy,”Neurology,vol.73,no.10,pp.781– 789,
  2. (2009). C o o p e r ,M .S .v a nd e rL o e ff,a n dG .P .T a y l o r
  3. (1991). Clinical manifestations of human T-cell lymphotrophic virus type-Iassociated myelopathy and vesicopathy,”
  4. (2005). DeJong’s The Neurologic Examination, Lippincott Williams and Wilkins,
  5. (1987). Interrater reliability of a modified Ashworth scale of muscle spasticity,”
  6. (2002). L i m a ,G .R a b o l i n i ,M .M e n n a - B a r r e t o
  7. (1989). o m i n e ,K .Y o s h i d a ,H .Y a m a s h i t a ,a n dZ .M a s a k i ,“ V o i d i n g dysfunction in patients with human T-lymphotropic virus type-1-associated myelopathy(HAM),”Paraplegia,
  8. (2003). O r l a n d ,J .E n g s t r o m ,J .F r i d e ye ta l . ,“ P r e v a l e n c ea n d clinical features of HTLV neurologic disease in
  9. (2007). P.Oliveira,N.M.DeCastro,andE.M.Carvalho,“Urinaryand sexual manifestations of patients infected by HTLV-I,”
  10. (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability status scale
  11. (2009). T.Nakamura,“HTLV-I-associatedmyelopathy/tropicalspastic paraparesis (HAM/TSP): the role of HTLV-I-infected Th1 cells in the pathogenesis, and therapeutic strategy,”
  12. (2009). The prevalence of human T-cell lymphotropic virus type 1 in the general population is unknown,”
  13. (1996). Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis,”
  14. (2007). Urodynamic features of the voiding dysfunction
  15. (1991). Voiding dysfunction in patients with human
  16. (1991). Voiding dysfunction: patients with human T-lymphotropic-virus-type-1-associated myelopathy,”